Mylatabi (Eltrombopag)

Eltrombopag, the active ingredient in Mylatabi, is a thrombopoietin receptor agonist presented as an oral tablet for oral use. It treats thrombocytopenia associated with immune thrombocytopenia, aplastic anemia, and chronic hepatitis C‑associated thrombocytopenia.

GNH USA supplies Mylatabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Eltrombopag acts on the thrombopoietin pathway to raise platelet production in several hematologic conditions.

Immune thrombocytopenia (ITP): Increases platelet counts to reduce bleeding risk. Aplastic anemia: Stimulates megakaryocyte development to improve platelet numbers. Chronic hepatitis C‑associated thrombocytopenia: Elevates platelet levels to support antiviral therapy and reduce bleeding complications.

Eltrombopag may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Diarrhea: loose stools, often transient. - Fatigue: general tiredness. - Elevated liver enzymes: mild hepatic enzyme changes. - Headache: occasional throbbing pain. - Cough: dry or productive.

Serious or Rare Side Effects: - Hepatotoxicity: significant liver injury requiring monitoring. - Thromboembolic events: blood clots in veins or arteries. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Myelosuppression: unexpected drop in other blood cell lines. - Hypersensitivity: anaphylaxis or severe allergic response.

Before initiating therapy, clinicians should evaluate patient history and monitor laboratory parameters.

Baseline liver function tests: assess hepatic safety before and during treatment. Complete blood count monitoring: track platelet response and detect marrow suppression. Avoid concomitant hepatotoxic drugs: reduce risk of liver injury. Pregnancy and lactation: use only if benefits outweigh potential risks. Drug‑specific contraindications: do not use in patients with known hypersensitivity to eltrombopag. Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Eltrombopag may interact with several medicines, altering efficacy or safety.

Major Interactions (Avoid): - Antacids containing aluminum or magnesium: markedly reduce absorption. - Iron supplements: significantly decrease oral bioavailability. - CYP3A4 inducers (e.g., rifampin, carbamazepine): lower plasma concentrations. - Strong chelating agents: impair drug uptake. - Live vaccines: potential reduced immune response.

Moderate Interactions (Monitor Closely): - Warfarin: possible alteration of anticoagulant effect. - Statins metabolized by CYP3A4: may increase statin exposure. - Oral contraceptives: monitor for reduced efficacy. - Proton pump inhibitors: modest impact on absorption. - Herbal supplements (e.g., St. John’s wort): may affect metabolism.